Glycogen Synthase Kinase-3: A New Therapeutic Target in Mood Disorders
KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, cilt.23, sa.2, ss.193-198, 2013 (SCI-Expanded, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 23 Sayı: 2
- Basım Tarihi: 2013
- Doi Numarası: 10.5455/bcp.20130624022007
- Dergi Adı: KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.193-198
- Marmara Üniversitesi Adresli: Evet
Özet
Mood disorders, including major depressive disorder and bipolar disorder, are common and largely inadequately treated. Additionally, little is known about their etiologies. Glycogen synthase kinase-3 (GSK-3) is a serine/threonine protein kinase, interacting with many signaling pathways. In 1996, lithium was found to inhibit GSK-3 and this discovery led us to the possibility that impaired GSK-3 inhibition is related with mood disorders. In time, animal and human studies encouraged this finding. Evidence is reviewed that depression may be associated with impaired inhibitory control of GSK-3, and mania with hyperstimulation of GSK-3. Mood disorders may result in part from impairments in mechanisms controlling the activity of GSK-3 or GSK-3-regulated functions and substantial evidence supports the conclusion that bolstering the modulatory control of GSK-3 is an important component of the therapeutic actions of drugs used to treat mood disorders and that GSK-3 is a valid target for developing new therapeutic interventions. Future research should identify the causes of dysregulation of GSK-3 in mood disorders and the actions of GSK-3 that contribute to these diseases.